Ejrnaes et al., 2005 - Google Patents
Different diabetogenic potential of autoaggressive CD8+ clones associated with IFN-γ-inducible protein 10 (CXC chemokine ligand 10) production but not cytokine …Ejrnaes et al., 2005
View PDF- Document ID
- 2648460917203426668
- Author
- Ejrnaes M
- Videbaek N
- Christen U
- Cooke A
- Michelsen B
- von Herrath M
- Publication year
- Publication venue
- The Journal of Immunology
External Links
- 230000014509 gene expression 0 title abstract description 36
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kukreja et al. | Autoimmunity and diabetes | |
| Roep et al. | Immune modulation in humans: implications for type 1 diabetes mellitus | |
| Afzali et al. | Pathways of major histocompatibility complex allorecognition | |
| Thébault-Baumont et al. | Acceleration of type 1 diabetes mellitus in proinsulin 2–deficient NOD mice | |
| Zhang et al. | In situ β cell death promotes priming of diabetogenic CD8 T lymphocytes | |
| Agarwal et al. | Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis | |
| Pulecio et al. | Expression of Wiskott-Aldrich syndrome protein in dendritic cells regulates synapse formation and activation of naive CD8+ T cells | |
| Yang et al. | Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis | |
| Perone et al. | Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune diabetes in mice | |
| Chandawarkar et al. | Immune modulation with high‐dose heat‐shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis | |
| Aricha et al. | Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis | |
| Ford et al. | Peptide‐activated double‐negative T cells can prevent autoimmune type‐1 diabetes development | |
| US20150313977A1 (en) | Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom | |
| JP2015142578A (en) | Immunogenic peptides and their use in immune disorders | |
| Viret et al. | Thymus-specific serine protease controls autoreactive CD4 T cell development and autoimmune diabetes in mice | |
| JPH09503387A (en) | Cloned glutamate decarboxylase | |
| Ejrnaes et al. | Different diabetogenic potential of autoaggressive CD8+ clones associated with IFN-γ-inducible protein 10 (CXC chemokine ligand 10) production but not cytokine expression, cytolytic activity, or homing characteristics | |
| Yamanouchi et al. | Cross-priming of diabetogenic T cells dissociated from CTL-induced shedding of β cell autoantigens | |
| Du et al. | TGF-β signaling is required for the function of insulin-reactive T regulatory cells | |
| CA2110055C (en) | T cell receptor peptides as therapeutics for immune-related disease | |
| Matin et al. | Role of stromal‐cell derived factor‐1 in the development of autoimmune diseases in non‐obese diabetic mice | |
| US20120114675A1 (en) | Foxp3+ natural killer t-cells and the treatment of immune related diseases | |
| Firdessa-Fite et al. | Soluble antigen arrays efficiently deliver peptides and arrest spontaneous autoimmune diabetes | |
| ’t Hart et al. | AB cell-driven autoimmune pathway leading to pathological hallmarks of progressive multiple sclerosis in the marmoset experimental autoimmune encephalomyelitis model | |
| Moshkani et al. | CD23+ CD21highCD1dhigh B cells in inflamed lymph nodes are a locally differentiated population with increased antigen capture and activation potential |